Table 3.
Patients with | ANOVA model | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Healthy subjects | Vestibular disorders | Cerebellar disorders | Functional disorders | Hypokinetic disorders | Vascular disorders | Others | All | F(6, 365) | p | |
Adherence | ||||||||||
Days recorded [d] | 12.3 ± 1.9 | 12.2 ± 2.2 | 12.4 ± 1.2 | 12.1 ± 2.6 | 12.4 ± 1.3 | 11.8 ± 2.4 | 12.4 ± 1.4 | 12.3 ± 2.0 | 1.1 | n.s |
Time sensor 'on' [%] | 96 ± 12 | 96 ± 6 | 99 ± 6 | 95 ± 15 | 98 ± 4 | 96 ± 12 | 97 ± 9 | 97 ± 9 | 0.2 | n.s |
Volume | ||||||||||
Step count [#] | 10,208 ± 3,299 | 8,316 ± 3,293* | 6,305 ± 3,302* | 8,251 ± 3,162* | 4,949 ± 3,606* | 8,696 ± 4,265* | 7,545 ± 3,941* | 7,981 ± 3761 | 9.5 | < 0.001 |
Ambulation time [%] | 8.7 ± 2.6 | 7.4 ± 2.6* | 5.7 ± 2.5* | 7.3 ± 2.4* | 4.4 ± 2.9* | 7.7 ± 3.3 | 6.7 ± 3.1 | 7.0 ± 2.9 | 10.3 | < 0.001 |
Sedentary time [%] | 27.8 ± 7.7 | 31.4 ± 8.9* | 34.5 ± 10.2* | 28.5 ± 8.2 | 37.6 ± 9.7* | 26.6 ± 6.7 | 29.2 ± 7.9 | 30.6 ± 9.2 | 7.9 | < 0.001 |
Sleep time [%] | 40.8 ± 6.7 | 40.9 ± 8.1 | 42.3 ± 9.9 | 43.8 ± 9.9* | 41.8 ± 14.8 | 43.6 ± 10.7* | 45.2 ± 11.6* | 42.3 ± 9.5 | 1.1 | n.s |
Activity | ||||||||||
Ambulation bouts [#] | 456 ± 134 | 413 ± 118 | 338 ± 139* | 418 ± 133 | 247 ± 130* | 439 ± 165 | 374 ± 174 | 396 ± 149 | 8.6 | < 0.001 |
Ambulatory bout duration [s] | 17 ± 5 | 16 ± 4 | 15 ± 4 | 16 ± 4 | 15 ± 4 | 15 ± 4 | 16 ± 4 | 16 ± 4 | 1.9 | n.s |
Daily intensity [MET] | 35 ± 1 | 34 ± 1 | 33 ± 1* | 34 ± 1 | 33 ± 2* | 34 ± 2 | 34 ± 2 | 34 ± 2 | 10.2 | < 0.001 |
Pattern | ||||||||||
Ambulation alpha | 1.42 ± 0.04 | 1.43 ± 0.02 | 1.43 ± 0.04 | 1.42 ± 0.03 | 1.43 ± 0.03 | 1.43 ± 0.03 | 1.42 ± 0.02 | 1.42 ± 0.03 | 0.8 | n.s |
Sit–walk transitions [#] | 40 ± 16 | 39 ± 16 | 36 ± 13 | 38 ± 15 | 30 ± 12 | 38 ± 17 | 41 ± 23 | 38 ± 16 | 1.4 | n.s |
Results from the 14 day continuous mobility tracking in the different clinical subgroups and healthy subjects. Mobility parameters are arranged with respect to the physical activity domains volume, activity, and pattern
*Significant difference in the Sheffé post hoc comparison (compared to healthy subjects)